Study on the Anti-Tumor Effect of CSF-1R Inhibitor Combined with Chemotherapy in the Treatment of Ovarian Cancer

FeI Song

doi:10.47297/wspbdsWSP2752-630504.20240404

PDF
Export
Share
Collection
Album

Study on the Anti-Tumor Effect of CSF-1R Inhibitor Combined with Chemotherapy in the Treatment of Ovarian Cancer

Volume 4, Issue 4

Views: 0 Downloads: 0

Study on the Anti-Tumor Effect of CSF-1R Inhibitor Combined with Chemotherapy in the Treatment of Ovarian Cancer
Study on the Anti-Tumor Effect of CSF-1R Inhibitor Combined with Chemotherapy in the Treatment of Ovarian Cancer
China Medical University, Shenyang, Liaoning, 110122
Vol. 4, Issue 4, Pages: 23-29(2024)
Published： 25 December 2024 ，
DOI：10.47297/wspbdsWSP2752-630504.20240404
Accepted：

Scan QR Code

FEI SONG. (2024). Study on the Anti-Tumor Effect of CSF-1R Inhibitor Combined with Chemotherapy in the Treatment of Ovarian Cancer. Biomedical Data Science, 4(4), 23-29..
DOI：

FEI SONG. (2024). Study on the Anti-Tumor Effect of CSF-1R Inhibitor Combined with Chemotherapy in the Treatment of Ovarian Cancer. Biomedical Data Science, 4(4), 23-29.. DOI： 10.47297/wspbdsWSP2752-630504.20240404.

摘要

Abstract

CSF-1R (Colony Stimulating Factor-1 Receptor) inhibitors

as novel targeted drugs in anti-tumor therapy

have shown potential in inhibiting tumor progression and alleviating immune suppression by reducing the activity of tumor-associated macrophages (TAMs) within the tumor microenvironment. In recent years

the combination of CSF-1R inhibitors with traditional chemotherapy drugs has achieved promising progress in the treatment of ovarian cancer. Research has found that CSF-1R inhibitors not only help mitigate chemotherapy resistance but also significantly improve the tumor microenvironment

thereby prolonging progression-free survival (PFS) and overall survival (OS) in patients. This paper summarizes existing preclinical and clinical research data and discusses the challenges and future prospects of this combined therapy in clinical applications.

关键词

Keywords

CSF-1R inhibitorovarian cancercombination chemotherapyanti-tumor efficacytumor microenvironment

references

Park J ,Cho W H ,Lim C M , et al. OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer. [J]. Future oncology (London, England), 2024, 1-7.

Wu C ,Yan J ,Wu Y . The efficacy, safety, and beneficiary population of angiogenesis inhibitor apatinib plus chemotherapy in recurrent platinum-resistant ovarian cancer patients: A comparative cohort study. [J]. The journal of obstetrics and gynaecology research, 2024, 50(8): 1345-1354.

Chen H ,Li R ,Wu J . The efficacy of tyrosine kinase inhibitors combined with chemotherapy for recurrent ovarian cancer: a systematic review and network meta-analysis [J]. Minerva Biotecnologica, 2024, 36(2): 81.

Adamu M S ,Oyewole S O ,Kabir F U . Efficacy and safety of combination of poly-ADP-ribose polymerase inhibitor (PARPi) and chemotherapy compared with chemotherapy alone in treatment of recurrent ovarian carcinoma: a systematic review. [J]. Nigerian medical journal : journal of the Nigeria Medical Association, 2024, 65(1): 11-15.

Yuan B ,Ping G ,Dan L , et al. Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report [J]. Frontiers in Oncology, 2022.

S. F ,A. P ,G. R ,et al. 562TiP A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer [J]. Annals of Oncology, 2021, 32 (S5): S618.

Peyraud F, Cousin S, Italiano A. CSF-1R inhibitor development: current clinical status[J]. Current Oncology Reports, 2017, 19: 1-10.

Cannarile M A, Weisser M, Jacob W, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy[J]. Journal for immunotherapy of cancer, 2017, 5(1): 53.

Cersosimo F, Lonardi S, Ulivieri C, et al. CSF-1R in cancer: More than a myeloid cell receptor[J]. Cancers, 2024, 16(2): 282.

Wen J, Wang S, Guo R, et al. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment[J]. European Journal of Medicinal Chemistry, 2023, 245: 114884.

Lu X, Meng T. Depletion of tumor-associated macrophages enhances the anti-tumor effect of docetaxel in a murine epithelial ovarian cancer[J]. Immunobiology, 2019, 224(3): 355-361.

Xun Q, Wang Z, Hu X, et al. Small-molecule CSF1R inhibitors as anticancer agents[J]. Current medicinal chemistry, 2020, 27(23): 3944-3966.

Valero J G, Matas-Céspedes A, Arenas F, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma[J]. Leukemia, 2021, 35(9): 2635-2649.

Tomassetti C, Insinga G, Gimigliano F, et al. Insights into CSF-1R Expression in the Tumor Microenvironment[J]. Biomedicines, 2024, 12(10): 2381.

Dowlati A, Harvey R D, Carvajal R D, et al. LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial[J]. Investigational New Drugs, 2021, 39: 1057-1071.

Alert me when the article has been cited

Submit

No data

Related Author

No data

Related Institution

No data

⁰